Simplified triple NRTI regimen effective in vertically infected children: two years follow-up

HIV Treat Bull - Vol. 7, No. 5, May 2006

Guido Castelli-Gattinara from Bambino Gesu hospital in Rome presented findings from a study evaluating a switch from protease based HAART to a simplified triple nucleoside regimen in a group of 20 vertically infected children.

The aim of the study was to evaluate long-term capacity to control viral replication; maintain immune reconstitution; reduce toxicity and improve quality of life.

Children with at least 24 months of undetectable viral load (<50 copies/mL) during PI-based treatment were enrolled in this single-arm non-randomised study. The triple nucleoside regimen was either AZT or d4T, plus abacavir and 3TC.

The children’s median age at switch was 8.1 years (range 3-18 years) and mean length of PI-based HAART was 50 months. Of 20 patients, 7 were treated since the first months of age; 8 were symptomatic when treated and 6 presented with severe immune deficiency prior to starting HAART.

At study entry, all children had undetectable viral load for a median of 36 months; a good CD4 percentage (mean 34.5%), good clinical health, and normal growth percentiles.

After a median follow up of 108 weeks (60 to 132 weeks), of triple nucleoside treatment all but one patient maintained undetectable viral load, plus good CD4 percentages, clinical and growth parameters. The one virological failure was in an adolescent boy who stopped treatment for personal reasons. The investigators attributed this failure to the development of the M184V mutation (M361/M and L63P mutations were also observed).

The investigators reported that after a median of 60 weeks, 8/20 children (40%) experienced blips (viral load >50 and <1000 copies/mL), but returned to undetectable levels. Additionally they found that total cholesterol decreased from a mean of 187 to 147 mg/dL, LDL decreased from 113 to 81 mg/dL, and triglycerides from 91.8 to 74mg/dL. They also found a progressive increase of specific CTL response in some children.

The researchers concluded that in this small study: “HAART simplification after an induction therapy allows to maintain a complete and long-term immunological and virological control with significant improvement of dyslipidemia. The progressive increase of specific cytotoxic T-lymphocyte response observed in some patients can be related to an enhanced viral replication in lymph nodes or an increased frequency of blips.”

Ref: Castelli-Gattinara G, Amicosante M, Palma P et al. 3-NRTI HAART simplification in children Is effective in maintaining virological and immunological control after 108 weeks. 13th CROI, Denver, 2006. Abstract 18.

2008-03-10
IB060705-20

©2008. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.